Published in Gut on September 01, 1970
Inflammatory bowel disease in West Indians. Br Med J (1976) 1.11
Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol (2013) 1.07
Ulcerative colitis in a developing country of Africa: the Baragwanath experience of the first 46 patients. Int J Colorectal Dis (1988) 0.92
The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med (2015) 0.82
The geographical incidence of chronic ulcerative colitis in Britain. Gastroenterology (1955) 1.76
Idiopathic ulcerative colitis in the African: a report of 4 cases. Br Med J (1966) 1.53
Ulcerative post-dysenteric colitis. Gut (1966) 1.26
Ulcerative colitis in the tropics. Br Med J (1967) 1.13
Surgical treatment of ulcerative colitis. Br Med J (1968) 0.92
Medical management of ulcerative colitis. Br Med J (1968) 0.91
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J (1972) 3.05
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis (1981) 2.27
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med (1982) 2.14
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J Clin Microbiol (1991) 2.12
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol (1996) 2.07
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev (1996) 1.90
Risk factors for second urinary tract infection among college women. Am J Epidemiol (2000) 1.88
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun (1993) 1.84
Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis (1993) 1.81
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med (1986) 1.81
Liver abscess caused by Streptococcus milleri. Rev Infect Dis (1989) 1.71
Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol (1990) 1.69
Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun (1994) 1.68
Development and verification of fingerprinting probes for Candida glabrata. Microbiology (1997) 1.67
Vulvovaginal candidiasis--what we do and do not know. Ann Intern Med (1984) 1.67
Immediate effects of intravenous propranolol on various cardiac arrhythmias. Am J Cardiol (1966) 1.67
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol (1985) 1.64
Polymorphonuclear leucocyte function in Behçet's disease. J Clin Pathol (1977) 1.59
Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med (1997) 1.58
Micafungin: a new echinocandin. Clin Infect Dis (2006) 1.58
Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol (1998) 1.57
Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun (1995) 1.56
Escape-capture bigeminy. Mechanisms in S-A block, A-V block, and reversed reciprocal rhythm. Br Heart J (1965) 1.52
Comparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans. J Clin Microbiol (1993) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun (1995) 1.48
Experimental chronic vaginal candidosis in rats. Sabouraudia (1985) 1.46
Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis (1993) 1.45
Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. J Infect Dis (1986) 1.42
Electrotonic inhibition of an idioventricular escape focus by nonconducted sinus impulses. Am Heart J (1988) 1.41
Bacterial adherence in the pathogenesis of urinary tract infection: a review. Rev Infect Dis (1987) 1.41
Irregularity of an escape rhythm related to the preceding cycle length. Am Heart J (1988) 1.38
Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol (1992) 1.38
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol (1994) 1.38
Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis (2001) 1.35
A murine model of Candida glabrata vaginitis. J Infect Dis (1996) 1.35
The Wenckebach phenomenon in sino-atrial block. Br Heart J (1966) 1.34
Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med (1993) 1.31
Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol (1992) 1.28
The role of cell-mediated immunity in candidiasis. Trends Microbiol (1994) 1.27
Immediate effects of intravenous verapamil on atrial fibrillation. Cardiovasc Res (1971) 1.27
Ketoconazole in the prevention of experimental candidal vaginitis. Antimicrob Agents Chemother (1984) 1.26
Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med (1995) 1.23
Histohogical and direct immunofluorescence study of cutaneous hyperreactivity in Behçet's disease. Br J Dermatol (1976) 1.21
Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol (1992) 1.21
Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates. J Clin Microbiol (1997) 1.21
Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis (2000) 1.19
Syphilitic posterior uveitis: correlative findings and significance. Clin Infect Dis (2001) 1.19
Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis. Antimicrob Agents Chemother (1983) 1.18
Personal experience. S Afr Med J (1976) 1.17
Adherence of bacteria to vaginal epithelial cells at various times in the menstrual cycle. Infect Immun (1981) 1.17
Genesis and evolution of ectopic ventricular rhythm. Br Heart J (1966) 1.17
Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis (1993) 1.16
The theory and mechanism of the Wenckebach phenomenon. S Afr Med J (1967) 1.16
Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis (1997) 1.15
Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother (1984) 1.14
Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol (1997) 1.14
Metronidazole-resistant vaginal trichomoniasis--an emerging problem. N Engl J Med (1999) 1.13
Mechanisms in reciprocal rhythm. Am J Cardiol (1969) 1.13
Polymorphonuclear leukocyte and monocyte chemoattractants produced by human fibroblasts. J Clin Invest (1979) 1.10
Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis (1994) 1.10
Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis (1999) 1.06
Cutaneous hyperreactivity in Behçet's disease. Dermatologica (1973) 1.05
Transmission of uropathogens between sex partners. J Infect Dis (1997) 1.05
Current debate on the use of antibiotic prophylaxis for caesarean section. BJOG (2011) 1.05
Idioventricular tachycardia. Dis Chest (1969) 1.04
Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis (2001) 1.03
Significance of retrograde conduction in A-v dissociation. Br Heart J (1965) 1.03
Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol (2001) 1.03
Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis (2000) 1.02
Parvovirus B19 infection in human pregnancy. BJOG (2010) 1.02
Pancreatic ascites treated by irradiation of pancreas. Br Med J (1971) 1.02
High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother (1999) 1.01
Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect Immun (1995) 1.01
In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob Agents Chemother (1995) 1.00
Comparison of bacterial and fungal adherence to vaginal exfoliated epithelial cells and human vaginal epithelial tissue culture cells. Infect Immun (1982) 1.00
Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis (1998) 1.00
Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis (2001) 0.99
Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. J Infect Dis (2000) 0.98
Zinc status in women with recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1986) 0.97
Saccharomyces cerevisiae vaginitis: transmission from yeast used in baking. Obstet Gynecol (1995) 0.96
The Wenckebach phenomenon in left bundle branch block. Am J Cardiol (1969) 0.96
Epidemiology of vulvar vestibulitis syndrome: an exploratory case-control study. Sex Transm Infect (1999) 0.96